Hookipa Pharma Inc (NASDAQ:HOOK – Get Free Report) saw a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 315,900 shares, a decrease of 5.2% from the March 15th total of 333,400 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average daily volume of 562,100 shares, the short-interest ratio is currently 0.6 days.
Hookipa Pharma Price Performance
Shares of Hookipa Pharma stock opened at $0.76 on Thursday. The firm has a market cap of $75.45 million, a PE ratio of -0.87 and a beta of 1.02. Hookipa Pharma has a 1 year low of $0.41 and a 1 year high of $2.05. The stock has a fifty day moving average price of $0.73 and a 200-day moving average price of $0.65.
Hookipa Pharma (NASDAQ:HOOK – Get Free Report) last posted its quarterly earnings data on Friday, March 22nd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. The business had revenue of $7.41 million during the quarter, compared to the consensus estimate of $3.60 million. Hookipa Pharma had a negative net margin of 405.28% and a negative return on equity of 72.30%. As a group, equities analysts anticipate that Hookipa Pharma will post -0.51 EPS for the current fiscal year.
Institutional Investors Weigh In On Hookipa Pharma
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $6.50 price target on shares of Hookipa Pharma in a report on Monday, March 25th. Royal Bank of Canada restated an “outperform” rating and issued a $5.00 target price on shares of Hookipa Pharma in a research note on Monday, March 25th.
View Our Latest Analysis on HOOK
Hookipa Pharma Company Profile
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Read More
- Five stocks we like better than Hookipa Pharma
- Options Trading – Understanding Strike Price
- United Airlines Soars on Earnings Beat
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- The 3 Best Fintech Stocks to Buy Now
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.